Page last updated: 2024-12-07
nephritogenoside
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
nephritogenoside: isolated from a variety of tissue types; receptor glycoprotein for concanavalin A from rat glomerular basement membrane [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 121932 |
| CHEBI ID | 175877 |
| MeSH ID | M0064584 |
Synonyms (14)
| Synonym |
|---|
| CHEBI:175877 |
| 81276-22-4 |
| (2r,3s,4r,5r)-2,3,4,5-tetrahydroxy-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal |
| nephritogenoside |
| nephritogenic glycopeptide |
| nephritogenic glycoprotein |
| nephritogenic glycoprotein, mouse |
| nephritogenoside protein, rat |
| nephritogenic glycoprotein, human |
| nephritogenoside protein, human |
| nephritogenoside protein, mouse |
| d-glucose, o-alpha-d-glucopyranosyl-(1-6)-o-d-glucopyranosyl-(1-6)- |
| nephritogenic glycoprotein, rat |
| (2r,3s,4r,5r)-2,3,4,5-tetrahydroxy-6-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}hexanal |
Research Excerpts
Overview
Nephritogenoside is a glycopeptide with the ability to induce chronic progressive glomerulonephritis (end stage kidney) in homologous animals, by a single footpad injection.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Nephritogenoside is a minor component of the basement membrane of normal animals (including humans). " | ( The structure of nephritogenoside. Ogihara, Y; Sawaki, M; Shibata, S; Takeda, T, 1989) | 2.06 |
| "Nephritogenoside is a glycopeptide with the ability to induce chronic progressive glomerulonephritis (end stage kidney) in homologous animals, by a single footpad injection. " | ( The structure of nephritogenoside. A nephritogenic glycopeptide with alpha-N-glycosidic linkage. Natori, Y; Shibata, S; Takeda, T, 1988) | 2.06 |
Effects
| Excerpt | Reference | Relevance |
|---|---|---|
| "Nephritogenoside has been prepared by coupling of the acyl azide derivative of a N-triglycosyl dipeptide, derived from the corresponding hydrazide derivative of O-(2,3,4,6-tetra-O-acetyl-alpha-D-glucopyranosyl)-(1-->6)-O-(2,3,4-tri-O -acetyl - beta-D-glucopyranosyl)-(1-->6)-2,3-di-O-benzyl-1-N-[N-(tert-butoxycarbon yl)- L-aspart-1-oyl-(L-proline methyl ester)-4-oyl]-alpha-D-glucopyranosylamine, with a nonadecapeptide, followed by deprotection of the desired protected nephritogenoside. " | ( Syntheses of nephritogenoside and related compounds. Kojima, K; Ogihara, Y; Takeda, T, 1993) | 2.1 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| O-acyl carbohydrate | A carbohydrate derivative in which the hydrogen atom of at least one alcoholic hydroxy group of a carbohydrate has been replaced by an acyl substituent. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (24)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 19 (79.17) | 18.7374 |
| 1990's | 4 (16.67) | 18.2507 |
| 2000's | 1 (4.17) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 10.77
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (10.77) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 5 (20.83%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 19 (79.17%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||